1. Home
  2. Detail

@sir.henry.backup: Dm 📞0718270297 or 0720388332 / 0182097779📌We are located at Nairobi Ronald Ngala street ,ROYALPALMS MALL.The building is (Next to Naivas /opposite Umoinner stage ) Wing B first floor shop BM58.#sirhenrycollection#fyp#goviral

Sir Henry back-up
Sir Henry back-up
Open In TikTok:
Region: KE
Friday 18 September 2026 14:01:17 GMT
522
27
1
2

Music

Download

No Watermark .mp4 (0.84MB) No Watermark(HD) .mp4 (0.84MB) Watermark .mp4 (2.25MB) Music .mp3

Comments

njengahspartah
Spartahdettah vendettah :
how much
2026-09-18 14:59:43
0
To see more videos from user @sir.henry.backup, please go to the Tikwm homepage.

Other Videos
Hearts touching right?🥺😥 …#ronaldomotivation #christiano Ronaldo #christianoronaldo #cr7 #fy
Hearts touching right?🥺😥 …#ronaldomotivation #christiano Ronaldo #christianoronaldo #cr7 #fy
😂♥️♥️. .. #foryoupage #تصميم_فيديوهات🎶🎤🎬 #viralvideo #حب #عبدالباسط_حمودة
😂♥️♥️. .. #foryoupage #تصميم_فيديوهات🎶🎤🎬 #viralvideo #حب #عبدالباسط_حمودة
Punya Anak Kecil? Pengguna PCX, NMAX, Aerox, ADV Wajib Siapkan Jok Ini!#jokboncengananak #jokanak #pcx160 #aksesorispcx
Punya Anak Kecil? Pengguna PCX, NMAX, Aerox, ADV Wajib Siapkan Jok Ini!#jokboncengananak #jokanak #pcx160 #aksesorispcx
#briannaolsen #santos #briolsen #briandsantos #fyp
#briannaolsen #santos #briolsen #briandsantos #fyp
Three recent obesity studies caught my attention for three very different reasons: One looked at a rare vision complication reported with GLP-1 medications. One asked whether semaglutide’s cardiovascular benefits differed in people who were already frail. And one followed people with obesity and prediabetes for three years to see what happened to both weight and progression to type 2 diabetes. What I like about putting these studies together is that they show how much bigger obesity medicine is than “how much weight did someone lose?” We’re studying long-term health outcomes, uncommon safety signals, different patient populations, and whether treatment can change the trajectory of obesity-related disease. And, as always, the details matter: an observational association is not the same thing as causation, a post-hoc analysis has limitations, and results from a specific clinical-trial population shouldn’t automatically be generalized to everyone. This is what I mean when I say obesity medicine is about a lot more than the number on the scale. #ObesityMedicine #ObesityResearch #GLP1 #Semaglutide #Tirzepatide
Three recent obesity studies caught my attention for three very different reasons: One looked at a rare vision complication reported with GLP-1 medications. One asked whether semaglutide’s cardiovascular benefits differed in people who were already frail. And one followed people with obesity and prediabetes for three years to see what happened to both weight and progression to type 2 diabetes. What I like about putting these studies together is that they show how much bigger obesity medicine is than “how much weight did someone lose?” We’re studying long-term health outcomes, uncommon safety signals, different patient populations, and whether treatment can change the trajectory of obesity-related disease. And, as always, the details matter: an observational association is not the same thing as causation, a post-hoc analysis has limitations, and results from a specific clinical-trial population shouldn’t automatically be generalized to everyone. This is what I mean when I say obesity medicine is about a lot more than the number on the scale. #ObesityMedicine #ObesityResearch #GLP1 #Semaglutide #Tirzepatide

About

Legal